Human Granulocytic Anaplasmosis and Anaplasma phagocytophilum by Dumler, J. Stephen et al.
Human granulocytic anaplasmosis is a tickborne rick-
ettsial infection of neutrophils caused by Anaplasma
phagocytophilum. The human disease was first identified in
1990, although the pathogen was defined as a veterinary
agent in 1932. Since 1990, US cases have markedly
increased, and infections are now recognized in Europe. A
high international seroprevalence suggests infection is
widespread but unrecognized. The niche for A. phagocy-
tophilum, the neutrophil, indicates that the pathogen has
unique adaptations and pathogenetic mechanisms.
Intensive study has demonstrated interactions with host-
cell signal transduction and possibly eukaryotic transcrip-
tion. This interaction leads to permutations of neutrophil
function and could permit immunopathologic changes,
severe disease, and opportunistic infections. More study is
needed to define the immunology and pathogenetic mech-
anisms and to understand why severe disease develops in
some persons and why some animals become long-term
permissive reservoir hosts.
H
uman granulocytic anaplasmosis (HGA) was first
identified in 1990 in a Wisconsin patient who died
with a severe febrile illness 2 weeks after a tick bite (1).
During the terminal phases of the infection, clusters of
small bacteria were noted within neutrophils in the periph-
eral blood (Figure 1), assumed to be phagocytosed gram-
positive cocci. A careful review of the blood smear
suggested the possibility of human ehrlichiosis, an emerg-
ing infection with similar bacterial clusters in peripheral
blood monocytes among infected patients in the southeast
and south-central United States. All blood cultures were
unrevealing, and specific serologic and immunohisto-
chemical tests for Ehrlichia chaffeensis, the causative
agent of human monocytic ehrlichiosis (HME) were nega-
tive. Over the ensuing 2 years, 13 cases with similar intra-
neutrophilic inclusions were identified in the same region
of northwestern Wisconsin and eastern Minnesota (2).
Aside from the bacterial clusters, common features among
these persons included fever, headache, myalgia, malaise,
absence of skin rash, leukopenia, thrombocytopenia, and
mild injury to the liver.
In 1994, through application of broad range molecular
amplification and DNA sequencing, the causative agent
was recognized as distinct from E. chaffeensis. The agent
was initially named HGE agent (1,2), although morpholog-
ic and serologic studies indicated a close or identical rela-
tionship to the veterinary pathogens of neutrophils, E. equi
and E. (Cytoecetes) phagocytophila. During the process of
classification of the human agent, phylogenetic studies
showed taxonomic disarray among organisms broadly
referred to as ehrlichiae, and a careful reorganization now
places those bacteria previously classified as E. phagocy-
tophila, E. equi, and the HGE agent into a different genus
as a single species, A. phagocytophilum (Figure 2) (1,3).
The fallout from the reclassification of these organisms is
the proposal for a complete revision of the families
Rickettsiaceae and Anaplasmataceae. Under the proposed
revision, the tribe structure of the Rickettsiaceae would be
abolished, and species in the Ehrlichieae tribe would be
assigned to the family Anaplasmataceae, with several
placed into the genera Ehrlichia (Cowdria ruminantium),
Anaplasma (E. equi, E. phagocytophila, HGE agent, E.
platys, E. bovis), and Neorickettsia (E. sennetsu and E. ris-
ticii). The genera Ehrlichia and  Anaplasma possess all
pathogens in the family that are transmissible by ticks and
that generally infect peripheral blood cellular elements,
including leukocytes, platelets, and erythrocytes.
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USAHGA is increasingly recognized as an important and
frequent cause of fever after tick bite in the Upper
Midwest, New England, parts of the mid-Atlantic states,
northern California, and many parts of Europe, all areas
where Ixodes ticks bite humans (4–6). The ecology of A.
phagocytophilum is increasingly understood. The bacteri-
um is maintained in a transmission cycle with Ixodes per-
sulcatus complex ticks, including I. scapularis in the
eastern United States, I. pacificus in the western United
States, I. ricinus in Europe, and probably I. persulcatus in
parts of Asia. Tick infection is established after an infec-
tious blood meal, and the bacterium is transstadially but
not transovarially passed (3). The major mammalian reser-
voir for A. phagocytophilum in the eastern United States is
the white-footed mouse, Peromyscus leucopus, although
other small mammals and white-tailed deer (Odocoileus
virginianus) can also be infected. White-footed mice have
transient (1–4 weeks) bacteremia; deer are persistently and
subclinically infected. Human infection occurs when
humans impinge on tick–small mammal habitats (4–7).
HGA is clinically variable, but most patients have a
moderately severe febrile illness with headache, myalgia,
and malaise. Among 10 clinical studies that describe the
findings in HGA across North America and Europe and
that comprise up to 685 patients (Table), the most frequent
manifestations are malaise (94%), fever (92%), myalgia
(77%), and headache (75%); a minority have arthralgia or
involvement of the gastrointestinal tract (nausea, vomiting,
diarrhea), respiratory tract (cough, pulmonary infiltrates,
acute respiratory distress syndrome [ARDS]), liver, or cen-
tral nervous system (4–7). Rash is observed in 6%,
although no specific rash has been associated with HGA
and co-infection with Borrelia burgdorferi, which can
cause simultaneous erythema migrans, is not infrequent.
Frequent laboratory abnormalities identified in up to 329
patients include thrombocytopenia (71%), leukopenia
(49%), anemia (37%), and elevated hepatic transaminase
levels (71%). 
Recent seroepidemiologic data suggest that many
infections go unrecognized, and in endemic areas as much
as 15% to 36% of the population has been infected (16,17).
In Wisconsin, the yearly incidence of HGA from 1990 to
1995 was as high as 58 cases/100,000 in 1 county (Lyme
disease incidence in the same region was 110
cases/100,000) (5). The overall yearly Connecticut inci-
dence rate from 1997 to 1999 was 24 to 51 cases/100,000
population (18). Symptomatic infection in Europe appears
to be rare; 66 cases have been reported, despite a median
seroprevalence rate of 6.2% among 35 published reports,
with rates as high as 21% in some European studies.
Similarly, the median infection prevalence in European I.
ricinus ticks is 3% (45 publications), a figure close to that
observed among North American I. scapularis and I. paci-
ficus ticks (median 4.7% among 42 publications). 
What is unclear from these data is whether the discrep-
ancy between the seroprevalence and symptomatic rate
results from underdiagnosis of infection, asymptomatic
serologic reactions, or even infections that produce cross-
reactive serologic responses. In any case, symptomatic
infection can occur often in tick-endemic regions and
varies in severity from mild, self-limited fever to death.
Severity sufficient for hospitalization is observed in half of
symptomatic patients and is associated with older age,
higher neutrophil counts, lower lymphocyte counts, ane-
mia, the presence of morulae in leukocytes, or underlying
immune suppression (5). Approximately 5%–7% of
patients require intensive care, and at least 7 deaths have
been identified (2,4,5,7,19), in which delayed diagnosis
and treatment were risk factors. Severe complications
include a septic or toxic shock–like syndrome, coagulopa-
thy, atypical pneumonitis/acute respiratory distress syn-
drome (ARDS), acute abdominal syndrome, rhabdomyo-
lysis, myocarditis, acute renal failure, hemorrhage,
brachial plexopathy, demyelinating polyneuropathy, cra-
nial nerve palsies, and opportunistic infections. At least 3
of the deaths resulted from opportunistic fungal or viral
infections or hemorrhage that occurred immediately after
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Figure 1. Anaplasma phagocytophilum in human peripheral blood
band neutrophil (A. Wright stain, original magnification ×1,000), in
THP-1 myelomonocytic cell culture (B, LeukoStat stain, original
magnification, ×400), in neutrophils infiltrating human spleen (C,
immunohistochemistry with hematoxylin counterstain; original
magnification ×100), and ultrastructure by transmission electron
microscopy in HL-60 cell culture (D; courtesy of V. Popov; original
magnification ×21,960).HGA. In 2 cases, the patients had reasons for preexisting
immunocompromise, which suggests that an intact
immune system is important for recovery and that HGA
further antagonizes immune dysfunction (2,4,5,7). Unlike
results of animal observations (20), no evidence has shown
A. phagocytophilum persistence in humans.
Pathology of A. phagocytophilum
Infections in Humans
Few histopathologic studies of HGA have been con-
ducted. Of 7 patients with fatal cases, 3 died from oppor-
tunistic infections (2,4,5,7), including exsanguination
after ulcerative Candida esophagitis, ulcerative herpes
simplex virus esophagitis with cryptococcal pneumonia,
and invasive pulmonary aspergillosis. In 2 other deaths,
the patients experienced myocarditis (likely viral) or gen-
eralized lymphadenopathy and mononuclear phagocyte
system activation.
The pathologic changes in humans include perivascular
lymphohistiocytic inflammatory infiltrates in multiple
organs, hepatitis with infrequent apoptoses, normocellular
bone marrow, mild lymphoid depletion, mononuclear
phagocyte hyperplasia in spleen and lymph nodes, and,
rarely, splenic necrosis. Hemophagocytosis is observed in
bone marrow, liver, and spleen. Vasculitis has not been
observed (4). By immunohistochemical tests, A. phagocy-
tophilum is rarely identified; organisms were abundant in
only 1 patient who died, rare in 2 patients, and not identi-
fied in 2 patients (2,4,5,19). Infected neutrophils are not
generally associated with pathologic lesions, which sug-
gests alternative mechanisms that do not involve direct
bacteria-mediated injury. 
Opportunistic infections and inflammatory changes in
humans are not unexpected because similar findings occur
in animals (19,21). In fact, tickborne fever (ruminant gran-
ulocytic anaplasmosis) induces diminished CD4 and CD8
peripheral blood counts, impaired mitogenic responses,
impaired antibody responses, impaired neutrophil emigra-
tion, and defective phagocytosis and intracellular killing.
Such in vitro findings are supported by clinical observa-
tions, which document that bacterial, fungal, and viral
infections are frequent and generally worse in animals with
tickborne fever (20). Disseminated staphylococcal infec-
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Figure 2. Current phylogeny and taxonomic classification of gen-
era in the family Anaplasmataceae. The distance bar represents
substitutions per 1,000 basepairs. E. coli, Escerichia coli.tions that occur with tickborne fever kill ≈2% of field-
raised sheep in the United Kingdom (20); louping ill, a
tickborne viral encephalitis of goats is self-limited unless it
occurs in conjunction with tickborne fever, when it is often
fatal (20); bacterial and fungal secondary infections are
more frequent in A. phagocytophilum–infected horses
(21). A likely interpretation is that A. phagocytophilum is
associated with perturbations in host inflammatory and
immune system function. Impaired early inflammatory
responses that might be induced by A. phagocytophilum
could contribute to the pathogenesis of HGA, and early
initiation of proinflammatory and immune responses
depend on functionally competent neutrophils and
mononuclear phagocytes.
Pathogenesis of A. phagocytophilum Infections
Anaplasma species are small (0.2–1.0 µm in diameter)
obligate intracellular bacteria with a gram-negative cell
wall (4), but lack lipopolysaccharide biosynthetic machin-
ery (22). The bacteria reside in an early endosome, where
they obtain nutrients for binary fission and grow into a
cluster called a morula (Figure 1). Recent genomic studies
demonstrated a type IV secretion apparatus, which could
facilitate transfer of molecules between the bacterium and
the host (23,24). A. phagocytophilum prefers to grow in
myeloid or granulocytic cells and has been propagated in
human HL-60 and KG-1 promyelocytic leukemia cells,
THP-1 myelomonocytic cells, endothelial cell cultures,
and tick cell cultures (3). HL-60 cells induced to differen-
tiate into neutrophil-like cells cease to divide but enhance
A.  phagocytophilum growth. When differentiated into
monocytic cells, HL-60 cells no longer support A. phago-
cytophilum growth.
A. phagocytophilum binds to fucosylated and sialylated
scaffold proteins on neutrophil and granulocyte surfaces
(25). The most studied ligand is PSGL-1 (CD162) to
which the bacterium adheres at least in part through 44-
kDa major surface protein-2 (Msp2) (26). Msp2 is proba-
bly part of an “adhesin complex” involving Msp2
oligomers with other membrane proteins. After internaliza-
tion of bacteria, the endosome ceases to mature and does
not accumulate markers of late endosomes or phagolyso-
somes (27). As a result, the vacuole does not become acid-
ified or fuse to lysosomes. A. phagocytophilum divides
until cell lysis or bacteria are discharged to infect other
cells.
The range of described A. phagocytophilum proteins is
limited, although the genome sequence should assist in
defining bacterial structure and function. The most abun-
dant protein in A. phagocytophilum is Msp2, encoded by a
multigene family of at least 22 paralogs in the Webster
strain genome and 52 or more paralogs in the HZ strain
genome (28). Antigenic diversity among A. phagocy-
tophilum strains from different regions is increased by
msp2 gene conversion. Diversity is assumed to be driven
by immune selection and may play an important role in
persistence among reservoir hosts, but restricted msp2
transcription and Msp2 expression over many passages
and in tick cells suggest selection by fitness for new nich-
es, a finding underscored by Msp2’s role as an adhesin
(26,28).
Aside from msp2, ankA is the most actively studied A.
phagocytophilum component (24,29). This gene encodes a
153–160 kDa protein with at least 11 N-terminal ankyrin
repeats and a C-terminus with several tandem repeats but
no homology with other proteins. AnkA sequences are
diverse according to geographic origin, with relative con-
servation among North American strains and diversity
among European bacteria. Whether ankA diversity relates
to severity is not known. An interesting observation
regarding AnkA is its localization, where it forms a com-
plex with chromatin in the infected granulocyte cell nucle-
us. Although little is known about whether AnkAaffects A.
phagocytophilum survival or pathogenesis, it is currently
the only protein of A.  phagocytophilum known to be
secreted by the bacterium, that passes through the bacteri-
al and vacuolar membrane (presumably by the A. phagocy-
tophilum type IV secretion mechanism [23]), through the
cytoplasm and nuclear membrane, to find a nuclear target.
Within the nucleus of infected neutrophils or HL-60 cells,
AnkA binds nuclear proteins and complexes to AT-rich
nuclear DNAthat lacks specific conserved sequences (29).
Its mere presence in the nucleus of a cell in which gene
transcription appears to be altered by infection compels
further investigation of a direct pathogenetic role in regu-
lation of eukaryotic gene expression.
Animal Models and Immunopathogenicity
The discrepancy between bacterial load and histopatho-
logic changes with HGA suggests that disease relates to
immune effectors that inadvertently damage tissues. In
vivo human cytokine responses are dominated by interfer-
on-γ (IFNγ) and interleukin-10 (IL-10), but lack tumor
necrosis factor α (TNFα), IL-1β, and IL-4 (30), which
suggests a role for macrophage activation in recovery and
disease. A murine model shows a cytokine profile similar
to that in humans and reproduces histopathologic lesions in
infected humans, horses, and dogs (19). In this model, bac-
terial load peaks at day 7 and rapidly declines; IFNγ peaks
at day 10 and also declines in parallel. However,
histopathologic injury, minimal at days 7–10, peaks by day
14, and then resolves. This pattern suggests a role for IFNγ
in histopathology and restriction of infection, which is
confirmed since histopathologic lesions do not develop in
IFNγ knockout mice, but the mice have a 5- to 8-fold
increase in bacteremia levels (31). In contrast, IL-10
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not have increased bacteremia levels, yet histopathologic
lesions are significantly worse than controls. The mecha-
nisms of bacterial growth restriction seem clearly related
to INFγ production, but the role of NOS2 (iNOS) in this
process is unresolved. Activation of innate immune
responses through TLR2, TLR4, MyD88, TNFα, and
CYBB does not contribute to control of A. phagocy-
tophilum. Several murine models show no correlation
between histopathologic injury and bacterial load.
Likewise, infection of TLR2-, TLR4-, MyD88-, TNFα-,
and CYBB-knockout mice does not affect bacterial bur-
den, yet abrogates inflammatory tissue lesions. Such find-
ings support an immune triggering role for A.
phagocytophilum as a mechanism for disease.
While IFNγ and IL-10 are key markers or effectors of
injury with A. phagocytophilum infection, their source is
unclear. Infection of neutrophils and HL-60 cells differen-
tiated into neutrophil-like cells produces striking quantities
of CXC and CC chemokines, including IL-8, RANTES,
MIP1α, MIP1β, and MCP-1, but not IFNγ, IL-10, TNFα,
IL-1β, or IL-4 (32), suggesting that A. phagocytophilum
infection partially activates neutrophils. Akkoyunlu et al.
demonstrated a decreased bacteremia with antibody block-
ade of chemokine receptors (CXCR2) and in CXCR2
knockout mice (33). This presumably provides a survival
advantage to the bacterium by recruitment of new neu-
trophil host cells, increasing the blood concentrations of
infected cells that can be acquired by tick bite. In spite of
the increased bacteremia, no increase in histopathologic
lesions is noted, confirming previous studies. The disad-
vantage of chemokine production to the host is that recruit-
ment of inflammatory cells that are activated could
produce IFNγ-induced inflammation, leading to damage to
tissues.
Neutrophil Functional Changes with 
A. phagocytophilum Infection
Other notable alterations of neutrophil function and
physiology are observed with A. phagocytophilum infec-
tion. A. phagocytophilum survives its initial encounter by
detoxifying superoxide produced by neutrophil phagocyte
oxidase assembly, perhaps by virtue of bacterial superox-
ide dismutase (23,34). Although not yet shown in infected
neutrophils, infected HL-60 cells are unable to generate
respiratory bursts because of reduced transcription of com-
ponents of phagocyte oxidase, including gp91phox and
Rac2 (35,36). Although this defect seems limited to the
infected neutrophils and is a major mechanism that permits
intracellular infection, the reduction in phagocyte oxidase
may have other effects, including a reduction in local reg-
ulation of inflammation. This results from the inability of
phagocyte oxidase to degrade inflammatory mediators
such as leukotrienes, complement, and perhaps other com-
ponents. Another normal function of neutrophils is apopto-
sis, which regulates inflammation by programmed cell
death of activated neutrophils usually within 24 to 48
hours. The induction of apoptosis by A. phagocy-
tophilum–infected neutrophils is delayed ≈24 hours (37)
and also relates to maintained transcription of bcl2 family
genes and stabilization of the mitochondrial pathway that
ultimately prevents procaspase 3 processing (37). 
Infection by A. phagocytophilum results in significant
disruption of normal neutrophil function, including
endothelial cell adhesion and transmigration, motility,
degranulation, respiratory burst, and phagocytosis. A.
phagocytophilum–infected neutrophils and HL-60 cells are
inhibited from binding to systemic and brain microvascu-
lar endothelial cells, even under conditions of low shear
force (38). The adhesion defect results from the shedding
of neutrophil PSGL-1 and L-selectin, which mediate the
critical first step in inflammatory cell recruitment. This
inhibited recruitment occurs despite the rapid mobilization
of surface β2-integrins (CD11b/CD18) and ICAM-1
(CD54), which ordinarily mediate the second phase of
tight endothelial-cell binding. Thus, A. phagocytophilum–
infected neutrophils are inhibited from transmigrating
endothelial cell barriers in spite of stimulated motility.
Selectin “shedding” occurs because infected cells degran-
ulate, including an EDTA-inhibitable sheddase (metallo-
protease),  β2-integrins, CD66b, and other inflammatory
components such as matrix metalloproteases, which
includes gelatinase (MMP9) (38,39). Engagement of
opsonophagocytosis receptors and degranulation are usu-
ally accompanied by rapid cell death (apoptosis), but with
A. phagocytophilum, degranulation occurs over a pro-
longed period, potentially exacerbating inflammation,
especially with delayed apoptosis of infected neutrophils
(36,39,40). After recruitment, chemotactic migration, and
activation for respiratory burst, neutrophils are then acti-
vated for phagocytosis; however, this function is inhibited
in vivo and in vitro, perhaps in part resulting from alter-
ations of rac2 expression and loss of important surface
receptors (40). Altogether, the activated-deactivated phe-
notype of the A. phagocytophilum–infected neutrophil may
benefit the bacterium by increasing concentrations of
infected cells in the peripheral blood that are unresponsive
to tissue recruitment and may have a prolonged lifespan.
However, the cost to the host includes activation of neu-
trophils to participate in proinflammatory reactions while
they are unable to act as microbicidal effectors or regula-
tors of inflammation. 
Conclusions
Investigators of novel intracellular bacteria often
address unanswered questions by investigating processes
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investigating differences that have allowed the unique
niche to become occupied. Since A.  phagocytophilum,
along with E.  ruminantium,  E. ewingii, and Chlamydo-
phila pneumoniae are the only known bacteria to survive
and propagate within neutrophils, it seems most relevant
that investigation should focus on adaptations permissive
for neutrophil infection. What is clear is that this new tick-
borne infection has a great capacity to infect and cause dis-
ease in humans while maintaining a persistent subclinical
state in animal reservoirs. The disease processes appear to
be immune and inflammatory in nature, not directly related
to pathogen burden, and result by the triggering of a detri-
mental and poorly regulated host response. Recent investi-
gations have provided important phenotypic data on the
range of functional changes among A. phagocytophilum–
infected neutrophils and identified several compelling tar-
gets for study of fundamental pathogenetic processes.
Important areas that still need intense study include the bac-
terial triggers of host innate and inflammatory response and
the molecular and cellular mechanisms by which A. phago-
cytophilum influences cell function and ultimately causes
injury to host cells, tissues, and organs. Perhaps by devel-
oping a more comprehensive understanding of the basic
mechanisms underlying A. phagocytophilum–neutrophil/
host interactions, we can appropriately target strategies for
control and management.
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